Filing identity and reporting period
Important discrepancy: The request identifies Tuhura Biosciences, Inc., but the supplied Form 10-Q is for Kintara Therapeutics, Inc. (Nasdaq: KTRA), a clinical-stage cancer drug developer. It covers the quarter and six months ended December 31, 2021, filed February 11, 2022. Financial amounts below are in U.S. dollars, in thousands, unless stated otherwise.
Financial results and liquidity
- Revenue: None to date; the company says it has no current prospect of revenue until product candidates are commercialized or partnered. Margins are therefore not meaningful.
- Quarter ended December 31, 2021: R&D expense was $3,902, up 51% from $2,584; general and administrative expense was $1,993, down 29% from $2,794; net loss was $5,893 versus $5,413. Loss per share was $0.12 versus $0.22.
- Six months ended December 31, 2021: R&D expense was $7,695, up 95% from $3,941; G&A was $4,171, down 4% from $4,329; net loss was $11,859 versus $24,931. Loss per share was $0.35 versus $1.34. The prior-year loss included $16,094 of acquired in-process R&D expense and $500 of merger costs; the current period included a $2,462 Series C stock dividend affecting loss attributable to common stockholders.
- Cash flow: Operating cash used was $10,177 for the six months, compared with $9,541 in the prior-year period. Financing provided $13,704, including $13,634 net proceeds from a September 2021 registered direct offering. Cash increased by $3,527 to $14,064.
- Balance sheet and liquidity: At December 31, cash was $14,064, current assets $14,998, current liabilities $3,438, working capital $11,560, total assets $17,718, and total liabilities $3,616. The balance sheet reports a $178 milestone payment liability; no conventional borrowings are listed at period end. Management estimates available cash funds planned operations for less than one year from the financial statements’ issuance and states substantial doubt exists about continuing as a going concern within one year.
- Capital and dilution: Common shares outstanding were 49.013 million at December 31 and 49.057 million on February 9, 2022. At quarter-end, 19.152 million common-stock warrants and 10.089 million stock options were outstanding; 17.177 million Series C preferred shares were also outstanding and convertible into approximately 14.789 million common shares, before considering applicable limitations and terms.
Changes, outlook, and material risks
- Higher R&D spending chiefly reflected ongoing enrollment and site costs for the VAL-083 GBM AGILE study, plus REM-001 development and manufacturing activity. Management expected fiscal 2022 R&D spending to exceed fiscal 2021 levels.
- The company’s lead programs are VAL-083 for glioblastoma and REM-001 for cutaneous metastatic breast cancer. Management expected VAL-083 GBM AGILE top-line results around the end of calendar 2023. Planned milestones included a first European Union study site in Q1 2022, first REM-001 confirmatory-study patient in Q2 2022, and REM-001 top-line results in Q3 2023. These are forward-looking targets, not assured outcomes.
- Management is pursuing additional equity financing and/or strategic partnerships; it warned that funding may not be available on acceptable terms and that programs could be tailored, delayed, reduced, or discontinued. Additional equity or convertible financing could dilute shareholders.
- COVID-19 had not significantly affected reported VAL-083 study enrollment, but the company reported contract-manufacturing and supply delays for REM-001 that could affect its timeline. Management also cited uncertainty in capital markets.
- Nasdaq had granted an extension to June 1, 2022, to regain compliance with the $1.00 minimum bid-price requirement. Failure to regain compliance or satisfy other listing requirements could lead to delisting and impair liquidity and access to capital.
- Other notable items: Series C dividends were paid in shares, creating a $2,462 noncash charge to common-stockholder results; the company reported no legal proceedings and no off-balance-sheet arrangements. Disclosure controls were assessed as effective, with no material change in internal control over financial reporting reported.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Kintara Therapeutics, Inc., not Tuhura Biosciences, Inc.
- Assess cash runway against operating cash use, trial spending, and the stated need for additional financing; verify any subsequent financing or partnership updates.
- Track clinical-trial enrollment, manufacturing and supply progress, and whether the stated VAL-083 and REM-001 milestones were achieved or revised.
- Review the potential dilution from common warrants, options, and convertible Series C preferred stock, including dividend and conversion terms.
- Check Nasdaq listing compliance and the status of the company’s going-concern risk disclosures.